CIM
HRMY icon

Cambria Investment Management’s Harmony Biosciences HRMY Stock Holding History

Cambria Investment Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-310,908
Closed -$10.7M – 406
2024
Q4 		$10.7M Sell
310,908
-20,643
-6% -$709K 0.65% 80
2024
Q3 		$13.3M Buy
+331,551
New +$11.6M 0.8% 42

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Cambria Investment Management's HRMY Position: Q1 2025 in Review

Cambria Investment Management sold out of Harmony Biosciences (HRMY) in Q1 2025, closing a stake of 310,908 shares — an estimated $10.7M sold.

Cambria Investment Management first reported a position in HRMY in Q3 2024 and held it in 2 quarters. The position peaked at $13.3M in Q3 2024. 272 funds tracked by Wall St. Rank hold HRMY as of Q1 2025.

  • Cambria Investment Management reported no remaining Harmony Biosciences position as of Q1 2025 after selling out during the quarter.
  • Cambria Investment Management sold 310,908 Harmony Biosciences shares in Q1 2025, an estimated $10.7M.
  • Cambria Investment Management first reported a position in Harmony Biosciences in Q3 2024 and held it in 2 quarters.
  • Cambria Investment Management's Harmony Biosciences position peaked at $13.3M in Q3 2024.
  • 272 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2025.

Based on Cambria Investment Management's 13F filing for Q1 2025, filed 15 May 2025.